Teva has launched both the AirDuo RespiClick fluticasone propionate/salmeterol DPI and an authorized generic version of the product in the US, the company said. The FDA approved 3 doses of AirDuo RespiClick for the treatment of asthma in patients aged 12 years and over earlier this year.
The company said that it expects the majority of sales to come from the generic fluticasone propionate/salmeterol multi-dose DPI.
Teva President and CEO of Global Specialty Medicines Rob Koremans commented, “With the launch of AirDuo RespiClick and its authorized generic, our intent is to meet the needs of patients, providers, and payers in the US seeking greater access to lower-cost asthma inhaler technology, while also allowing Teva to compete in the highly competitive asthma combination controller market. This important launch marks not only the first available generic ICS/LABA product in the US, but also the continued expansion of our RespiClick family of products, which now includes breath-activated inhaler options for both maintenance treatment and rescue medication.”
Read the Teva press release.
